-transparent.png){kind=logo}
1. Almitrine bismesylate displays wide inter-subject variation in peak plasma concentrations and can induce peripheral polyneuropathy. 2. The phenotyped volunteer panel approach was used to examine whether almitrine oxidation displayed a genetic polymorphism of the debrisoquine/sparteine type. 3. There was no difference between poor and extensive metabolisers of debrisoquine with respect to the pharmacokinetics and metabolism of almitrine.
Related Publications
A Herchuelz, and
D Gangji, and
F Derenne, and
J P Jeanniot, and
J Douchamps
June 1993,
Pain,
A Herchuelz, and
D Gangji, and
F Derenne, and
J P Jeanniot, and
J Douchamps
February 1994,
The Journal of pharmacology and experimental therapeutics,
A Herchuelz, and
D Gangji, and
F Derenne, and
J P Jeanniot, and
J Douchamps
January 1986,
European journal of clinical pharmacology,
A Herchuelz, and
D Gangji, and
F Derenne, and
J P Jeanniot, and
J Douchamps
January 1982,
European journal of clinical pharmacology,
A Herchuelz, and
D Gangji, and
F Derenne, and
J P Jeanniot, and
J Douchamps
September 2003,
European journal of clinical pharmacology,
A Herchuelz, and
D Gangji, and
F Derenne, and
J P Jeanniot, and
J Douchamps
January 1997,
European journal of clinical pharmacology,
A Herchuelz, and
D Gangji, and
F Derenne, and
J P Jeanniot, and
J Douchamps
November 1989,
Lancet (London, England),
A Herchuelz, and
D Gangji, and
F Derenne, and
J P Jeanniot, and
J Douchamps
April 1980,
Clinical pharmacology and therapeutics,
A Herchuelz, and
D Gangji, and
F Derenne, and
J P Jeanniot, and
J Douchamps
January 1996,
European journal of clinical pharmacology,
A Herchuelz, and
D Gangji, and
F Derenne, and
J P Jeanniot, and
J Douchamps
April 1994,
British journal of clinical pharmacology,
